Fleury stock: Citi lifts target ahead of Q3 results

On October 6, Citi raised its price target for Fleury from BRL 16 to BRL 23 while retaining a neutral rating, according to El Fondo. The revision came as analysts lifted their earnings estimates for 2026 and 2027, citing a lower discount rate.

Estimates point to a busy quarter

Citi expects third-quarter revenue to increase 12.7 percent year over year, or 10 percent organically. The bank forecasts EBITDA of BRL 667 million and net income of BRL 257 million, with the profit estimate six percent above market expectations.

The main operating issue for investors is the recent integration of Femme. Citi expects the transaction to weigh on margins by about 30 basis points year over year. That makes the third-quarter release an early test of revenue growth, integration costs and profitability.

Results date is now in focus

Fleury's investor-relations website schedules the third-quarter 2026 earnings release for Thursday, November 5, after the market closes. The English-language conference call is set for Friday, November 6, at 9:00 a.m. New York time, according to Fleury Investor Relations.

Fleury's healthcare footprint

Fleury provides diagnostic imaging, clinical analysis, fertility and infusion services in Brazil through its Diagnostic Medicine and Integrated Medicine segments. Its portfolio also includes laboratory support and health-management services. Simply Wall St lists Bradsaúde, Rede D'Or São Luiz and Hospital Mater Dei among the comparison companies; its profile describes Fleury as a specialist healthcare group operating alongside larger diversified Brazilian healthcare businesses.

Brazilian equities remain part of the broader Current market reports landscape.

More news and analyses on Fleury stock.